Skip to main content

Table 3 Multivariate analysis PFS

From: NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice

MULTIVARIATE ANALYSIS (PFS)

 

HR

95 % CI

p

KPS

2,18

0,8–5,9

0,125

CA19.9 RESPONSE

0,27

0,1–0,68

0,006

NLR ≥ 5

3,84

1,6–9,2

0,002

BILIRUBIN

1,4

0,59–3,3

0,444

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us